D. Boral Capital Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective decreased by D. Boral Capital from $3.00 to $2.00 in a research note issued to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

LCTX has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Friday, January 31st. Maxim Group cut their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th.

Lineage Cell Therapeutics Trading Up 6.9 %

Shares of NYSEAMERICAN:LCTX opened at $0.69 on Tuesday. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61. The stock has a market cap of $150.99 million, a price-to-earnings ratio of -5.71 and a beta of 1.21.

Institutional Trading of Lineage Cell Therapeutics

A number of hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter worth about $46,000. Defender Capital LLC. lifted its position in Lineage Cell Therapeutics by 0.6% during the third quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock worth $4,528,000 after acquiring an additional 29,223 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Lineage Cell Therapeutics during the third quarter worth approximately $84,000. MAI Capital Management boosted its holdings in shares of Lineage Cell Therapeutics by 2.2% during the third quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after acquiring an additional 35,907 shares during the period. Finally, Raffles Associates LP boosted its holdings in Lineage Cell Therapeutics by 3.4% in the 3rd quarter. Raffles Associates LP now owns 4,507,781 shares of the company’s stock valued at $4,081,000 after purchasing an additional 150,000 shares during the period. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.